|EW-7197Selective inhibitor of TGF-β type I receptor kinase|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||1352608-82-2||SDF||Download SDF|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
IC50: 0.013 μM
Transforming growth factor-β (TGF-β) belongs to the TGF-β superfamily, which consists of TGF-β1, TGF-β2, TGF-β3. TGF-β and its receptors are often chronically overexpressed in various human diseases, such as cancer, tissue fibrosis, inflammation, and autoimmunity. Therefore, blockade of TGF-β signaling pathway is an attractive target for drug development. Following TGF-β binding to the constitutively active type II receptor, the type I receptor (ALK5) is phosphorylated and creates a binding site for Smad2/Smad3 proteins, which are further phosphorylated. EW-7197 is a highly potent, selective inhibitor of TGF-β type I receptor kinase.
In vitro: EW-7197 inhibited ALK5 with IC50 value of 0.013 μM in a kinase assay and with IC50 values of 0.0165 and 0.0121 μM in HaCaT stable cells and 4T1 stable cells, respectively, in a luciferase assay. Selectivity profiling of EW-7197 using a panel of protein kinases revealed that it is a highly selective ALK5/ALK4 inhibitor .
In vivo: EW-7197 inhibited Smad/TGF-βsignaling, invasion, cell migration, and lung metastasis in MMTV/c-Neu mice and 4T1 orthotopic–grafted mice. EW-7197 inhibited the epithelial-to-mesenchymal transition in both TGF-β-treated breast cancer cells and 4T1 orthotopic–grafted mice as well.
Clinical trial: The First in human dose escalation study of EW-7197 in subjects with advanced stage solid tumors is ongoing .
 Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl) -1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem. 2014 May 22;57(10):4213-38.
 Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, Sheen YY. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther. 2014 Jul;13(7):1704-16. doi: 10.1158/1535-7163.MCT-13-0903. Epub 2014 May 9.
 https://clinicaltrials. gov/ct2/show/NCT02160106?term=EW-7197&rank=1